Sutro Biopharma STRO Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's operating lease right-of-use assets in other assets?
- Sutro Biopharma (STRO) reported operating lease right-of-use assets in other assets of $9.71M in Q1 2026.
- How has Sutro Biopharma's operating lease right-of-use assets in other assets changed year-over-year?
- Sutro Biopharma's operating lease right-of-use assets in other assets decreased by 40.4% year-over-year, from $16.28M to $9.71M.
- What is the long-term trend for Sutro Biopharma's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Sutro Biopharma's operating lease right-of-use assets in other assets has grown at a -18.2% compound annual growth rate (CAGR), from $29.7M to $10.9M.